Immuneel Therapeutics
Type
startup
Founded
2018
Funding captured
$52.5m
Deals captured
4
About Immuneel Therapeutics
Develops, manufactures and commercializes cell and gene therapies for blood cancers, with a focus on CD19-targeting CAR‑T treatments for lymphoma and leukemia. Immuneel operates GMP manufacturing and clinical development capabilities in India and holds technology-transfer rights to develop and produce IMN-003A (varnimcabtagene autoleucel), marketed as Qartemi, enabling locally produced CAR‑T therapies aimed at improving access and affordability for patients in India and selected international markets.
Immuneel Therapeutics funding captured (4)
| Deal type | Stage | Date | Amount | Investors |
|---|---|---|---|---|
| Equity | Series B | Jun 8, 2026 | $10.5m | |
| **************** | **************** | **************** | $12.0m | **************** |
| **************** | **************** | **************** | $15.0m | **************** |
| **************** | **************** | **************** | $15.0m | **************** |
